Vanda Pharmaceuticals Inc. $VNDA Holdings Trimmed by Rhumbline Advisers

Rhumbline Advisers reduced its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 5.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 85,899 shares of the biopharmaceutical company’s stock after selling 5,040 shares during the period. Rhumbline Advisers owned about 0.15% of Vanda Pharmaceuticals worth $394,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. ProShare Advisors LLC increased its holdings in shares of Vanda Pharmaceuticals by 32.4% during the 4th quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 4,599 shares during the last quarter. MetLife Investment Management LLC lifted its position in shares of Vanda Pharmaceuticals by 18.9% during the 1st quarter. MetLife Investment Management LLC now owns 32,816 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 5,210 shares during the period. Hsbc Holdings PLC raised its position in Vanda Pharmaceuticals by 17.8% in the 1st quarter. Hsbc Holdings PLC now owns 56,594 shares of the biopharmaceutical company’s stock valued at $259,000 after purchasing an additional 8,545 shares during the last quarter. Quantinno Capital Management LP bought a new position in Vanda Pharmaceuticals in the 4th quarter valued at $48,000. Finally, Stonepine Capital Management LLC raised its position in shares of Vanda Pharmaceuticals by 40.6% during the first quarter. Stonepine Capital Management LLC now owns 35,148 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 10,148 shares during the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, August 21st. Wall Street Zen cut Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 2nd. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, Vanda Pharmaceuticals has a consensus rating of “Strong Buy” and a consensus price target of $16.50.

Vanda Pharmaceuticals Stock Up 2.9%

NASDAQ VNDA opened at $4.90 on Thursday. Vanda Pharmaceuticals Inc. has a twelve month low of $3.81 and a twelve month high of $5.55. The company has a market cap of $289.54 million, a price-to-earnings ratio of -4.34 and a beta of 0.74. The business’s fifty day moving average is $4.55 and its 200 day moving average is $4.53.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.12). Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%.The company had revenue of $52.59 million for the quarter, compared to the consensus estimate of $54.77 million. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.